Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Pascal Finetti
The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage
Abstract The excessive production of extracellular matrix (ECM) and the metabolic adaptations in pancreatic ductal adenocarcinoma (PDAC) contribute individually to enhanced chemoresistance, marked tumor progression, and dismal patient survival. However, ECM-driven metabolic alterations that promote chemoresistance in PDAC are so far unexplored. Here, we use in vitro–generated ECM bioscaffolds that recapitulate cell-ECM interactions and induce broad metabolic alterations in PDAC cells.
Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity - Oncogene
Multi-omic analysis of colorectal adenocarcinoma identifies a new subtype of myofibroblastic cancer-associated fibroblast expressing high level of B7-H3 and with poor prognosis value.
Abstract The high mortality rate of colorectal cancer (CRC) combined with the lack of non-toxic and efficient personalized treatments makes it urgent to develop new targeted therapies for this disease. B7-H3 appears to be a good target as it is overexpressed in tumor tissue compared to normal tissue. However, B7-H3 is a molecule with ambivalent functions and is expressed by different cell types.
Gene expression-based rationale for investigating CDK4/6 inhibitors in primitive myelofibrosis - Leukemia
Primitive myelofibrosis (PMF) is the most aggressive form of myeloproliferative neoplasms (MPNs), characterized by bone marrow fibrosis, leukocytosis and extra-medullary hematopoiesis (EMH) [1, 2]. The treatment options are limited. The currently approved JAK2 inhibitors (Ruxolitinib, Fedratinib) offer only symptomatic relief without significantly reducing fibrosis. Complete remissions similar to those observed in CML with ABL inhibitors, cannot be achieved with current JAK2 inhibitors in PMF.
Deciphering Folate Receptor alphaGene Expression and mRNA Signatures in Ovarian Cancer: Implications for Precision Therapies
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype
Article Dans Une Revue Pharmaceutics Année : 2023 Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype Mots clés LIV1 SLC39A6 ZIP6 breast cancer antibody–drug conjugates zinc transporter protein expression survival Domaines Cancer Génomique, Transcriptomique et Protéomique [q-bio.GN] Pharmacologie Fichier principal pharmaceutics-15-00938.pdf (1.57 Mo) Télécharger le fichier Origine : Fichiers éditeurs autorisés sur une archive ouverte hal-04390874...
Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer
http://orcid.org/0000-0002-3518-4845Raphael Rapetti-Mauss1, http://orcid.org/0000-0003-1358-1863Jérémy Nigri2, Camille Berenguier1, Pascal Finetti2, Sarah Simha Tubiana2, Bonnie Labrum1, Benoit Allegrini1, Bernard Pellissier1, Georgios Efthymiou2, http://orcid.org/0000-0002-5641-5569Zainab Hussain2, http://orcid.org/0000-0002-2501-0593Corinne Bousquet3, http://orcid.org/0000-0002-6161-8483Nelson Dusetti2, François Bertucci2, Hélène Guizouarn1, Patricia Melnyk4, Franck Borgese1,...
PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma
Abstract : Simple Summary Hepatocellular carcinoma (HCC) represents the third cause of cancer-related death in the world, and identification of new prognostic factors and/or therapeutic targets remains a major issue. Recently, immune checkpoint inhibitors (ICIs) have opened promising therapeutic options for this disease.
EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer
Information Published In Science Advances Volume 8 | Issue 50 December 2022 Copyright Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).
SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer
http://orcid.org/0000-0002-3518-4845Raphael Rapetti-Mauss1, http://orcid.org/0000-0003-1358-1863Jérémy Nigri2, Camille Berenguier1, Pascal Finetti2, Sarah Simha Tubiana2, Bonnie Labrum1, Benoit Allegrini1, Bernard Pellissier1, Georgios Efthymiou2, http://orcid.org/0000-0002-5641-5569Zainab Hussain2, http://orcid.org/0000-0002-2501-0593Corinne Bousquet3, http://orcid.org/0000-0002-6161-8483Nelson Dusetti2, François Bertucci2, Hélène Guizouarn1, Patricia Melnyk4, Franck Borgese1,...
Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer
Tumor Microenvironment and Immunobiology Kim C. Honselmann, Pascal Finetti, David J. Birnbaum, Christian S. Monsalve, Ulrich F. Wellner, Sebastian K.S. Begg, Akifumi Nakagawa, Thomas Hank, Annie Li, Mathew A. Goldsworthy, Himanshu Sharma, François Bertucci, Daniel Birnbaum, Eric Tai, Matteo Ligorio, David T. Ting, Oliver Schilling, Martin L. Biniossek, Peter Bronsert, Cristina R. Ferrone, Tobias Keck, Mari Mino-Kenudson, Keith D. Lillemoe, Andrew L. Warshaw, Carlos Fernández-del Castillo and Andrew S.
The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
Abstract The genomics-based molecular classifications aim at identifying more homogeneous classes than immunohistochemistry, associated with a more uniform clinical outcome. We conducted an in silico analysis on a meta-dataset including gene expression data from 5342 clinically defined ER+/HER2− breast cancers (BC) and DNA copy number/mutational and proteomic data.
ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer
Abstract Background Triple-negative breast cancers (TNBC) are poor-prognosis tumours candidate to chemotherapy as only systemic treatment. We previously found that PRICKLE1, a prometastatic protein involved in planar cell polarity, is upregulated in TNBC. We investigated the protein complex associated with PRICKLE1 in TNBC to identify proteins possibly involved in metastatic dissemination, which might provide new prognostic and/or therapeutic targets.
Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors
clear search menu Search for Articles: Logical OperatorOperator Submit to this Journal Review for this Journal Edit a Special Issue Article Menu /ajax/scifeed/subscribe Need Help? Support Find support for a specific problem in the support section of our website. Get Support Feedback Please let us know what you think of our products and services. Give Feedback Information Visit our dedicated information section to learn more about MDPI.
The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
The immunologic constant of rejection (ICR) is a broad phenomenon of Th-1 immunity-mediated, tissue-specific destruction. We tested the prognostic value of a 20-gene ICR expression signature in 8766 early breast cancers. Thirty-three percent of tumours were ICR1, 29% ICR2, 23% ICR3, and 15% ICR4. In univariate analysis, ICR4 was associated with a 36% reduction in risk of metastatic relapse when compared with ICR1-3 (p = 2.30E–03).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Pascal
Contact Pascal, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack